LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Affordable Blood-Based Test Provides Early Detection of Colorectal Cancer

By LabMedica International staff writers
Posted on 16 Mar 2023
Print article
Image: BeScreened-CRC is a screening test that aids in the detection of colorectal cancer (Photo courtesy of Beacon Biomedical)
Image: BeScreened-CRC is a screening test that aids in the detection of colorectal cancer (Photo courtesy of Beacon Biomedical)

Colorectal cancer (CRC) is the second most lethal and expensive cancer in the US, with over 150,000 new diagnoses and 50,000 deaths annually. Shockingly, of the 131 million Americans eligible for CRC screening each year, a massive 45 million opt out – accounting for 65% of CRC deaths and 75% of CRC treatment expenses (a hefty USD 18 billion each year) as well as lost productivity costs of USD 20 billion. Recent research has shown that 84% of the population prefers blood testing to fecal testing. Now, a newly-launched CRC blood test improves screening compliance and consequently, the probability of survival while sharply bringing down CRC treatment costs and eliminating the need for fecal collection.

Beacon Biomedical (Phoenix, AZ, USA) has announced the commercial release of the BeScreened Colorectal Cancer (CRC) test, a laboratory developed test (LDT) that meets the needs of average-risk men and women over 45 who prefer blood-based screening over colonoscopy or fecal-based tests. The BeScreened-CRC test is designed to drive improved compliance and early detection - which can result in survival rates of 90%, as against merely 14% if detected later. The test is the preferred blood-based modality, one of the most accurate tests in the industry with an accuracy rate of 94.6%, and is much more affordable than other available screening options.

"Too many lives are lost every year to colorectal cancer. The real tragedy is the majority of these deaths are preventable as they can be directly attributed to non-compliance with existing screening methods," said Don Weber, Founder & CEO of Beacon Biomedical. "As a simple, easy to adopt, and highly accurate blood-based test for CRC screening, BeScreened was developed to address this very problem."

Related Links:
Beacon Biomedical 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more